MedTrace Logo

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

NCT04507269 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-08-26

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

Placebo

Saline given by subcutaneous injection

Sponsors & Collaborators

  • Vir Biotechnology, Inc.

    collaborator INDUSTRY

  • Alnylam Pharmaceuticals

    collaborator INDUSTRY

  • Brii Biosciences Limited

    lead INDUSTRY

Principal Investigators

  • Xiaofei Chen · Brii Biosciences Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-18
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04507269 on ClinicalTrials.gov